Berenberg has revised its price target and earnings estimates for Galderma following the company's record first-half 2026 results, citing strength in the integrated model that combines injectables, skincare, and devices. The analyst's upgrade reflects confidence in Galderma's ability to cross-sell across product categories and geographies.
Business & M&A
Berenberg Backs Galderma's Integrated Model After H1 Beat
Analyst revises price target and estimates following strong first-half results.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Berenberg revises estimates upward, citing strength in Galderma's integrated injectables, skincare, and device model.
The integrated model—anchored by Botox and Juvéderm, bolstered by Alastin skincare, and supported by device partnerships—allows Galderma to capture multiple revenue streams from a single practice relationship. This structural advantage matters for practice owners evaluating supplier consolidation: a single Galderma rep can now address toxin, filler, skincare, and device needs, reducing the number of vendor relationships required. Berenberg's upgrade signals institutional confidence that this bundling strategy will sustain margin expansion and market share gains.
Source: original report ↗
Frequently asked questions
What is Galderma's integrated model and how does it work?
Galderma's integrated model combines injectables (Botox, Juvéderm), skincare (Alastin), and device partnerships into a single supplier relationship. This allows one Galderma representative to address toxin, filler, skincare, and device needs for a practice, reducing the number of vendor relationships required and enabling cross-selling across product categories and geographies.
Why did Berenberg upgrade Galderma after H1 2026 results?
Berenberg revised its price target and earnings estimates upward following Galderma's record first-half 2026 results, citing strength in the integrated model's ability to capture multiple revenue streams from single practice relationships. The upgrade reflects confidence that the bundling strategy will sustain margin expansion and market share gains.
What are the benefits of consolidating suppliers with Galderma?
Consolidating with Galderma reduces administrative overhead by replacing multiple vendor relationships with a single rep who can address toxins, fillers, skincare, and devices. This structural advantage allows practices to streamline procurement while maintaining access to a comprehensive product portfolio across categories.
How does Galderma's integrated model impact practice margins?
The integrated model enables margin expansion through cross-selling efficiency and reduced vendor management costs. By bundling injectables, skincare, and devices under one supplier relationship, practices can negotiate better terms and reduce the operational complexity of managing multiple vendor accounts.
What products anchor Galderma's integrated offering?
Botox and Juvéderm anchor the injectables portfolio, Alastin provides the skincare component, and device partnerships complete the offering. This combination allows Galderma to serve the full spectrum of aesthetic treatment modalities from a single vendor.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.